The role of the VEGF-C/VEGFR-3 axis in cancer progression - PubMed (original) (raw)

Review

The role of the VEGF-C/VEGFR-3 axis in cancer progression

J-L Su et al. Br J Cancer. 2007.

Abstract

Vascular endothelial growth factor (VEGF) receptor 3 (VEGFR-3) (also called VEGFR-3) is activated by its specific ligand, VEGF-C, which promotes cancer progression. The VEGF-C/VEGFR-3 axis is expressed not only by lymphatic endothelial cells but also by a variety of human tumour cells. Activation of the VEGF-C/VEGFR-3 axis in lymphatic endothelial cells can facilitate metastasis by increasing the formation of lymphatic vessels (lymphangiogenesis) within and around tumours. The VEGF-C/VEGFR-3 axis plays a critical role in leukaemic cell proliferation, survival, and resistance to chemotherapy. Moreover, activation of the VEGF-C/VEGFR-3 axis in several types of solid tumours enhances cancer cell mobility and invasion capabilities, promoting cancer cell metastasis. In this review, we discuss the novel function and molecular mechanism of the VEGF-C/VEGFR-3 axis in cancer progression.

PubMed Disclaimer

Similar articles

• Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node.
  Saintigny P, Kambouchner M, Ly M, Gomes N, Sainte-Catherine O, Vassy R, Czernichow S, Letoumelin P, Breau JL, Bernaudin JF, Kraemer M. Saintigny P, et al. Lung Cancer. 2007 Nov;58(2):205-13. doi: 10.1016/j.lungcan.2007.06.021. Epub 2007 Aug 7. Lung Cancer. 2007. PMID: 17686546
• [Correlation of lymphangiogenesis to progression of colorectal cancer].
  Wang TB, Huang YH, Lan P, Song XM, Wang JP. Wang TB, et al. Ai Zheng. 2005 Oct;24(10):1276-9. Ai Zheng. 2005. PMID: 16219148 Chinese.
• Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms.
  Kodama M, Kitadai Y, Tanaka M, Kuwai T, Tanaka S, Oue N, Yasui W, Chayama K. Kodama M, et al. Clin Cancer Res. 2008 Nov 15;14(22):7205-14. doi: 10.1158/1078-0432.CCR-08-0818. Clin Cancer Res. 2008. PMID: 19010837
• Molecular control of lymphatic metastasis.
  Achen MG, Stacker SA. Achen MG, et al. Ann N Y Acad Sci. 2008;1131:225-34. doi: 10.1196/annals.1413.020. Ann N Y Acad Sci. 2008. PMID: 18519975 Review.
• Pathways targeting tumor lymphangiogenesis.
  Wissmann C, Detmar M. Wissmann C, et al. Clin Cancer Res. 2006 Dec 1;12(23):6865-8. doi: 10.1158/1078-0432.CCR-06-1800. Clin Cancer Res. 2006. PMID: 17145802 Review.

Cited by

• Biomarkers of lymph node metastasis in colorectal cancer: update.
  Zhu X, Lin SQ, Xie J, Wang LH, Zhang LJ, Xu LL, Xu JG, Lv YB. Zhu X, et al. Front Oncol. 2024 Sep 12;14:1409627. doi: 10.3389/fonc.2024.1409627. eCollection 2024. Front Oncol. 2024. PMID: 39328205 Free PMC article. Review.
• Clinical efficacy of Apatinib combined with Epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI) in nonsmall cell lung cancer after EGFR-TKI resistance.
  Tian R, Guo Y, Zhang X, Zhang X, Song X. Tian R, et al. Pak J Med Sci. 2024 Sep;40(8):1714-1718. doi: 10.12669/pjms.40.8.9682. Pak J Med Sci. 2024. PMID: 39281226 Free PMC article.
• Correlation between Periostin Expression and Pro-Angiogenic Factors in Non-Small-Cell Lung Carcinoma.
  Wasik A, Podhorska-Okolow M, Dziegiel P, Piotrowska A, Kulus MJ, Kmiecik A, Ratajczak-Wielgomas K. Wasik A, et al. Cells. 2024 Aug 23;13(17):1406. doi: 10.3390/cells13171406. Cells. 2024. PMID: 39272978 Free PMC article.
• Lymphatic endothelial cell-targeting lipid nanoparticles delivering VEGFC mRNA improve lymphatic function after injury.
  Michalaki E, Chin R, Jeong K, Qi Z, Liebman LN, González-Vargas Y, Echeverri ES, Paunovska K, Muramatsu H, Pardi N, Tamburini BJ, Jakus Z, Dahlman JE, Dixon JB. Michalaki E, et al. bioRxiv [Preprint]. 2024 Jul 31:2024.07.31.605343. doi: 10.1101/2024.07.31.605343. bioRxiv. 2024. PMID: 39131391 Free PMC article. Preprint.
• Autotaxin-Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications.
  Laface C, Ricci AD, Vallarelli S, Ostuni C, Rizzo A, Ambrogio F, Centonze M, Schirizzi A, De Leonardis G, D'Alessandro R, Lotesoriere C, Giannelli G. Laface C, et al. Int J Mol Sci. 2024 Jul 15;25(14):7737. doi: 10.3390/ijms25147737. Int J Mol Sci. 2024. PMID: 39062979 Free PMC article. Review.

References

1. 1. Akagi K, Ikeda Y, Miyazaki M, Abe T, Kinoshita J, Maehara Y, Sugimachi K (2000) Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer 83: 887–891 - PMC - PubMed
2. 1. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y (2003) Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 97: 457–464 - PubMed
3. 1. Byzova TV, Goldman CK, Pampori N, Thomas KA, Bett A, Shattil SJ, Plow EF (2000) A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell 6: 851–860 - PubMed
4. 1. Chen F, Takenaka K, Ogawa E, Yanagihara K, Otake Y, Wada H, Tanaka F (2004) Flt-4-positive endothelial cell density and its clinical significance in non-small cell lung cancer. Clin Cancer Res 10: 8548–8553 - PubMed
5. 1. Chen Z, Varney ML, Backora MW, Cowan K, Solheim JC, Talmadge JE, Singh RK (2005) Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res 65: 9004–9011 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal